Calaspargase Pegol
Last Updated: 06/30/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 13 publications
Economic burden associated with switching from frontline pegaspargase or calaspargase pegol to second-line recombinant Erwinia in pediatrics and adolescents/young adults with acute lymphoblastic leukemia.
Journal: Journal of medical economics
Published: May 21, 2026
PKPD-Based Translational Modeling of Calaspargase Pegol Preclinical Activity in Hepatocellular Carcinoma.
Journal: European journal of drug metabolism and pharmacokinetics
Published: February 12, 2026
Variability in Calaspargase Pegol Administration and Monitoring Across U.S. Pediatric Oncology Centers.
Journal: Pediatric blood & cancer
Published: October 04, 2025
Severe hypertriglyceridemia associated with calaspargase pegol.
Journal: Leukemia & lymphoma
Published: August 09, 2025
Prolonged Therapeutic Serum Asparaginase Activity Levels After Administration of Calaspargase Pegol.
Prolonged Therapeutic Serum Asparaginase Activity Levels After Administration of Calaspargase Pegol.
Journal: Pediatric blood & cancer
Published: June 23, 2025
Asparagine synthetase promoter hypermethylation is required, but not sufficient, for sensitivity to Asparlas in patient-derived models of hepatocellular carcinoma.
Journal: European journal of pharmacology
Published: March 12, 2025
Desensitization to calaspargase pegol appears to be less successful than pegaspargase.
Journal: Blood advances
Published: November 25, 2024
Hepatic veno-occlusive disease with asparaginase products: a review of cases reported to the FDA adverse event reporting system and published in the literature.
Journal: Pediatric hematology and oncology
Published: August 28, 2024
Calaspargase pegol and pegaspargase cause similar hepatosteatosis in mice.
Journal: Haematologica
Published: August 27, 2024
Attempted desensitization to calaspargase pegol: a familiar approach to a new problem.
Journal: Leukemia & lymphoma
Published: November 22, 2023
Efficacy and Toxicity of Pegaspargase and Calaspargase Pegol in Childhood Acute Lymphoblastic Leukemia: Results of DFCI 11-001.
Journal: Journal of clinical oncology : official journal of the American Society of Clinical Oncology
Published: July 06, 2021
Improving the Treatment of Acute Lymphoblastic Leukemia.
Journal: Biochemistry
Published: August 14, 2020
Last Updated: 06/30/2026